

## [373] AIVF - TRANSFORMING IVF WITH THE POWER OF ARTIFICIAL INTELLIGENCE

**Daniella Gilboa<sup>1</sup>, Yonatan Dolan<sup>2</sup>, <sup>1</sup> Chief Scientific Officer and Co-Founder, AIVF, <sup>2</sup> Business Development Director**

- **Investment Rational**  
Over 180M women worldwide cannot conceive naturally and over 2.4M IVF treatments occur annually to help these women to overcome this extremely frustrating reality. Unfortunately, most IVF treatments fail and do not lead to the desired pregnancy. New methods to enhance IVF efficacy could offer an enormous opportunity to address an unmet medical need, improve the economic burden and increase success rates.
- **Business Strategy**  
AIVF aims to simplify the embryo selection process by providing clinicians and embryologists a fully automated AI-based decision support tool
- **Core Technology**  
Our solution easily integrates with existing IVF systems and provides a personalized prognostic report on the predicted viability of each embryo. Our proprietary AI algorithms are based on a large body of embryological data and years of IVF expertise input.
- **Product Profile/Pipeline**  
AIVF is currently in research phase to prove out the ability of an AI based algorithm to enhance embryo selection. The IVF market is estimated at \$15B with a CAGR of 15%; The company has strategic collaboration with 4 clinics in US, Spain, Israel and holds the largest dataset of over 200,000 time-lapse videos of developing embryos.
- **What's Next?**  
AIVF plan to present a proof-of-concepts results later this year, conduct a prospective clinical trial in Q1'20. Later in 2020 we target regulatory approval for usage of the system in clinics and first commercial sales in 2021. In parallel we are working to expand our network of clinics targeting to reach 6 clinics by year-end and a data set of over 300k time-lapse videos.